Soleno Therapeutics (SLNO) Competitors $88.30 +2.29 (+2.66%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. FEMY, IMVT, SNN, SOLV, PEN, STVN, GKOS, BLCO, IRTC, and TMDXShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), iRhythm Technologies (IRTC), and TransMedics Group (TMDX). These companies are all part of the "medical" sector. Soleno Therapeutics vs. Its Competitors Femasys Immunovant Smith & Nephew SNATS Solventum Penumbra Stevanato Group Glaukos Bausch + Lomb iRhythm Technologies TransMedics Group Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Does the media refer more to SLNO or FEMY? In the previous week, Soleno Therapeutics had 11 more articles in the media than Femasys. MarketBeat recorded 11 mentions for Soleno Therapeutics and 0 mentions for Femasys. Soleno Therapeutics' average media sentiment score of 1.07 beat Femasys' score of 0.00 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Soleno Therapeutics Positive Femasys Neutral Which has more risk & volatility, SLNO or FEMY? Soleno Therapeutics has a beta of -2.63, suggesting that its share price is 363% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.56, suggesting that its share price is 356% less volatile than the S&P 500. Which has higher earnings & valuation, SLNO or FEMY? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.62-19.11Femasys$1.63M17.46-$18.82M-$0.91-0.96 Do analysts prefer SLNO or FEMY? Soleno Therapeutics currently has a consensus price target of $108.70, suggesting a potential upside of 23.10%. Femasys has a consensus price target of $8.67, suggesting a potential upside of 890.48%. Given Femasys' higher probable upside, analysts plainly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SLNO or FEMY more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,242.06%. Soleno Therapeutics' return on equity of -77.52% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -77.52% -63.44% Femasys -1,242.06%-392.45%-137.15% Do institutionals & insiders hold more shares of SLNO or FEMY? 97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by company insiders. Comparatively, 11.5% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummarySoleno Therapeutics beats Femasys on 9 of the 16 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.44B$2.49B$5.63B$9.41BDividend YieldN/A1.80%4.01%4.02%P/E Ratio-19.079.2328.4320.05Price / SalesN/A589.75415.6587.96Price / CashN/A165.2635.9658.29Price / Book15.555.178.525.82Net Income-$175.85M$30.99M$3.24B$258.18M7 Day Performance3.26%4.34%4.58%3.68%1 Month Performance8.46%15.65%12.60%14.51%1 Year Performance82.45%-0.35%35.87%19.00% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.2954 of 5 stars$88.31+2.7%$108.70+23.1%+87.6%$4.44BN/A-19.0730Positive NewsFEMYFemasys2.4754 of 5 stars$0.94+1.6%$8.67+822.1%-21.8%$30.57M$1.70M-1.0330IMVTImmunovant1.5587 of 5 stars$18.59+2.5%$36.30+95.3%-35.9%$3.18BN/A-6.78120Positive NewsSNNSmith & Nephew SNATS3.1972 of 5 stars$30.06-0.7%$28.00-6.8%+9.1%$13.16B$5.81B13.9117,349SOLVSolventum1.0673 of 5 stars$74.08+0.4%$81.50+10.0%+34.7%$12.82B$8.25B34.3022,000Positive NewsPENPenumbra4.8901 of 5 stars$238.82+0.4%$305.07+27.7%+20.7%$9.25B$1.24B225.314,500Positive NewsUpcoming EarningsSTVNStevanato GroupN/A€25.55+1.3%N/A+12.2%€7.74B€1.12B50.105,521Gap UpGKOSGlaukos4.4623 of 5 stars$104.43+0.6%$134.67+29.0%-21.9%$5.97B$404.52M-44.06780Upcoming EarningsBLCOBausch + Lomb2.4866 of 5 stars$13.67-1.5%$15.45+13.1%-17.3%$4.83B$4.83B-13.2713,500Upcoming EarningsIRTCiRhythm Technologies1.3885 of 5 stars$138.91+2.2%$138.60-0.2%+34.7%$4.43B$591.84M-44.242,000Positive NewsTMDXTransMedics Group2.3116 of 5 stars$116.88+3.9%$127.33+8.9%-29.2%$3.95B$441.54M85.94210Upcoming EarningsGap Up Related Companies and Tools Related Companies Femasys Alternatives Immunovant Alternatives Smith & Nephew SNATS Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives Glaukos Alternatives Bausch + Lomb Alternatives iRhythm Technologies Alternatives TransMedics Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
